Dataset opportunity
Starseq — 医疗影像数据集机会
Starseq 持有的中等规模医疗影像数据集，可用于诊断人工智能和计算机视觉。
Score
45
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
56%
Action
数据共享协议
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market size (indicative estimate)
全球基因组人工智能市场预计到 2026 年将达到 17 亿美元，复合年增长率为 40.3%（2026-2033 年）（来源：Grand View Research）
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Concrete evidence this company actively cares about data — why it's ripe for the deal room.
Profile
Dataset profile
Type
医疗影像数据集
Modality
图像
Sector
医疗保健
Volume
中等
Freshness
定期
Rarity
中等
Accessibility
受限
Legal
混合所有权 — GDPR 敏感（个人身份信息审查）
Buyer persona
医疗人工智能和诊断影像公司
Starseq 持有一系列宝贵的专有基因集合及相关的研发数据集，结合了测序产生的基因组数据与关联的医疗影像和患者记录。该多模态数据集构成了一项重要的沉睡资产，非常适合用于训练和验证旨在进行生物标志物发现、疾病预测和个性化治疗路径的高性能诊断人工智能模型。
尽管存在访问复杂性，例如敏感基因信息的 GDPR 合规性以及需要隔离客户拥有的数据，但该资产的价值得到了蓬勃发展的市场的支撑。全球基因组人工智能市场预计将从 2026 年的17 亿美元增长到 2033 年的 188 亿美元，其增长的复合年增长率 (CAGR) 高达 40.3%。[1] 这使得 Starseq 独特且专有的数据成为买家开发下一代诊断工具的稀有且高度抢手的资源。⚠ 尽职调查（有价值的数据，可协商的访问权限）：基因组数据对 GDPR 高度敏感，需要严格的道德/法律合规性；标准的测序结果通常归客户所有，需要与专有研发数据明确区分；专有基因集合和研发数据集是主要的沉睡资产 · 公司：独立。
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
这些证据共同证明 Starseq 生成和策划了高价值的基因组数据，包括来自全外显子组测序和高通量分析的数据。该公司正在积极构建一个与人类疾病明确关联的新型基因专有集合，这是训练下一代诊断人工智能的核心资产。对于医疗人工智能和诊断公司而言，这是获得在基因组人工智能市场竞争所需基础数据的直接途径，该市场预计每年增长超过 40%。
See dimension details ↓- Dataset Specificity78
主导的“医疗记录”，医疗保健行业，2 种特定类型
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity46
专有领域数据（开放会降低稀有度）
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume58
4 个证据命中
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness62
API/开放（当前）
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value74
适用于诊断人工智能
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand95
人工智能买家需求异常高，这得益于基因组人工智能市场的快速扩张，复合年增长率为 40.3%，导致对专有基因组和临床数据集的竞争异常激烈。[1]
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility14
开放/API 访问
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility48
中等难度，独立
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength74
4 种证据类型，4 次命中
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License28
所有权=混合，许可=GDPR 敏感
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
独立
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation73
3 个数据需求信号（3 种类型）
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus92
盈余=高，4 个近期外部信号 — 超出已货币化数据的专有数据
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit50
⚠ 审查 — 这是一家提供收费服务的实验室，其核心业务是为客户生成 DNA 测序数据；它不拥有数据，因此没有可供出售的沉睡数据。问题：该公司的业务是提供 DNA 测序服务；由此产生的数据是交付给客户的，而不是 Starseq 拥有的专有副产品；该公司明确表示客户的“样本、结果、数据和知识产权是安全的”，这意味着客户保留所有权。[5]；最初
- Deep Qualification90
✓ 通过 — Starseq 主要是一家基因组服务提供商（CRO），这意味着其核心业务产生的数据归客户所有。然而，其内部研发项目，例如“GlioTraceGenOmics”，可能生成专有的多模态数据集（基因组学+临床数据），这些数据集代表了沉睡的资产。“Medic
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
press
- “<p>When Roche previewed the Axelios technology in February, a Jefferies analyst called the next-generation sequencing platform the “greatest credible competitive threat in years.”</p>”
- “<p>Queue is developing automated pharmacies to expand access to prescriptions in hospitals, retail sites, and underserved communities.</p> <p>The post <a href="https://www.therobotreport.com/queue-raises-funding-fully-autonomous-pharmacy/">Queue raises funding to build fully autonomous pharmacy</a> appeared first on <a href="https://www.therobotreport.com">The Robot Report</a>.</p>”
- “<p>The acquisition strengthens Agilent’s presence in areas including cancer and infectious disease diagnostic and research markets.</p>”
Downloads / exports
这些商业推广证据证实 Starseq 是一个活跃的、规模化的基因组测序服务提供商，表明了下一代测序 (NGS) 和微生物组数据的一致性操作流程。
Medical records / imaging
此样本证实了该公司在全外显子组测序和基因表达分析等高级分析方面的能力，这些正是生成诊断人工智能所需丰富基础数据的确切过程。
Data catalog / marketplace
这是战略性地构建与人类疾病相关的新型基因专有集合的直接证据，代表了用于人工智能开发的经过策划的高价值资产。
Industrial data
此样本展示了该公司在分子遗传学方面的广泛专业知识，包括微生物组分析，这为其数据生成能力提供了质量和多样性的基础。
Marketplace
Dataset details
Geographic coverage
Global
Time range
Not specified, likely historical with periodic updates
Update frequency
Periodic
Delivery
Likely secure file transfer or API access
License
One-time license for training and validation of diagnostic AI models, subject to GDPR and data segregation requirements.
Personal data
Contains PII
Indicative estimate, derived from public signals — not a quote, not contractual, and not agreed with the company. Is this your company? Correct it.
This multi-modal dataset, combining proprietary genomic data with linked medical imaging and patient records, is highly valuable for training diagnostic AI. The strong market growth in AI in Genomics supports a premium valuation.
Detailed schema & sample available on access request.
Want this data?
Request access — we broker a secure deal room. Operator-reviewed, no automatic sharing.
This listing was generated automatically from public signals. It is not verified, and we are not affiliated with this company.
Coverage
Scanned sources
Deliverable
Premium dataset report
Starseq Medical Imaging — a Moderate medical imaging dataset (Image modality) in the healthcare domain. Primary AI use-case: Diagnostic AI. Market signal: Global AI in Genomics market to reach USD 1.7 billion in 2026, with a 40.3% CAGR (2026-2033) (source: Grand View Research). Investment score 45.0/100 (confidence 0.56). Recommended action: Data Sharing Agreement.
From the marketplace
Explore live data opportunities
Nordicpowerservice — 检验报告数据集机会
View opportunity →工业Energiequelle — 数据集机会：维护日志
View opportunity →零售Salesupply — 交易数据集机会
View opportunity →